Climb Bio, Inc. (CLYM): who owns it and who trades it
As of Nov 16, 2026, CLYM insiders reported 6 open-market sales worth $2.7M and 3 purchases worth $780K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Stephen Basil Thomas (Director), with $2.2M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Climb Bio
From the latest filingsOverall: about as much buying as selling. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CLYM
109 funds and institutions reported CLYM shares worth $736M at the end of Q2 2026, about 99% of the company. The largest holder is Ra Capital Management, L.P. with 19.7%.
Funds and institutions (13F) 99%Everyone else 1%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 11.30M | 19.74% | $147M | No change |
| FMR LLC (Fidelity) | 6.79M | 11.86% | $88.5M | +106049% |
| UBS Group AG | 3.40M | 5.95% | $44.4M | +3862% |
| Braidwell LP | 2.80M | 4.89% | $36.5M | +83% |
| Adage Capital Partners Gp, L.l.c. | 2.51M | 4.38% | $32.7M | New |
| BlackRock, Inc. | 2.35M | 4.11% | $30.7M | +486% |
| T. Rowe Price Associates | 2.13M | 3.72% | $27.7M | +11% |
| Cormorant Asset Management, LP | 2.11M | 3.68% | $27.5M | New |
| Frontier Capital Management Co LLC | 1.94M | 3.39% | $25.3M | New |
| Vanguard Capital Management LLC | 1.70M | 2.97% | $22.2M | +44% |
| Woodline Partners LP | 1.58M | 2.76% | $20.6M | New |
| Citadel Advisors LLC | 1.30M | 2.27% | $16.9M | +276% |
| Redmile Group, LLC | 1.23M | 2.14% | $16M | New |
| Great Point Partners LLC | 1.00M | 1.75% | $13M | -25% |
| Affinity Asset Advisors, LLC | 972,000 | 1.70% | $12.7M | +39% |
| Millennium Management LLC | 908,198 | 1.59% | $11.8M | -29% |
| ADAR1 Capital Management, LLC | 822,649 | 1.44% | $10.7M | +38% |
| Driehaus Capital Management LLC | 790,000 | 1.38% | $10.3M | +31% |
| Geode Capital Management, LLC | 782,199 | 1.37% | $10.2M | +150% |
| Stempoint Capital LP | 742,745 | 1.30% | $9.7M | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CLYM insiders reported $780K of open-market purchases and $2.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Stephen Basil Thomas | Director | Sale | 100,000 | $13.67 | $1.4M | Form 4 |
| Jun 29, 2026 | Aoife Brennan | CEO | Sale | 30,902 | $13.17 | $407K | Form 4 |
| Feb 26, 2026 | Stephen Basil Thomas | Director | Sale | 16,313 | $7.01 | $114K | Form 4 |
| Feb 25, 2026 | Stephen Basil Thomas | Director | Sale | 33,687 | $7.00 | $236K | Form 4 |
| Feb 13, 2026 | Stephen Basil Thomas | Director | Sale | 10,000 | $5.81 | $58.1K | Form 4 |
| Feb 12, 2026 | Stephen Basil Thomas | Director | Sale | 90,000 | $5.23 | $471K | Form 4 |
| Jan 5, 2026 | RA Capital Healthcare Fund LP +6 | Director | Purchase | 7,111 | $3.50 | $24.9K | Form 4 |
| Dec 12, 2025 | Peter Kolchinsky +6 | Director | Purchase | 101,462 | $2.86 | $290K | Form 4 |
| Dec 11, 2025 | Peter Kolchinsky +6 | Director | Purchase | 213,099 | $2.18 | $465K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Stephen Basil Thomas | Director | – | $2.2M | Sep 15, 2026 |
| Peter Kolchinsky | Director, 10% owner | $755K | – | Dec 12, 2025 |
| Aoife Brennan | President and CEO, Director | – | $407K | Jun 29, 2026 |
| RA Capital Healthcare Fund LP | Director, 10% owner | $24.9K | – | Jan 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CLYM short interest
High short interest. 18.1% of CLYM shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 408%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.61M CLYM shares were sold short, 18.1% of the shares outstanding, up 8.5% from the report before. At the average daily volume of 1.37M shares, buying them all back would take about 7.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.61M | 18.07% | +8% | 1.37M | 7.8 |
| Oct 15, 2026 | 9.79M | 17.04% | +1% | 946,178 | 10.3 |
| Sep 30, 2026 | 9.72M | 16.92% | +14% | 1.72M | 5.6 |
| Sep 15, 2026 | 8.51M | 14.81% | +17% | 1.88M | 4.5 |
| Aug 31, 2026 | 7.30M | 12.71% | -3% | 1.23M | 5.9 |
| Aug 14, 2026 | 7.56M | 13.16% | +7% | 1.20M | 6.3 |
| Jul 31, 2026 | 7.04M | 12.25% | +2% | 1.04M | 6.8 |
| Jul 15, 2026 | 6.87M | 12.00% | +35% | 1.36M | 5.0 |
| Jun 30, 2026 | 5.10M | 8.90% | +70% | 1.73M | 3.0 |
| Jun 15, 2026 | 3.00M | 5.24% | +57% | 1.53M | 2.0 |
| May 29, 2026 | 1.91M | 3.33% | -9% | 676,327 | 2.8 |
| May 15, 2026 | 2.09M | 3.65% | +18% | 972,970 | 2.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Climb Bio company events
Climb Bio filed 19 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 26, 2026AnnouncementThe Company announced initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in pMN and minimal change disease. Filing
- Oct 23, 2026AnnouncementThe Company announced additional data from the Phase 1 clinical development program of CLYM116 in healthy volunteers. Filing
- Sep 3, 2026AnnouncementShared information with investors. Filing
- Aug 14, 2026AnnouncementBeijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, which is being conducted in collaboration with Climb Bio, Inc. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 1, 2026LeadershipAndrew Levin notified the board of directors of Climb Bio, Inc. of his resignation as a member of the Board, effective immediately. Filing
- Jun 12, 2026AgreementClimb Bio, Inc., a Delaware corporation, entered into an Open Market Sale Agreement℠ with Jefferies LLC, as agent, pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share, from time to time through Jefferies. Filing
- Jun 11, 2026AnnouncementClimb Bio, Inc. announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia: • The Phase 1b portion of the Phase 1b/2a study (NCT07043946) is evaluating three ascending… Filing
- Jun 8, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Climb Bio, Inc. held on June 5, 2026, the Company’s stockholders approved an amendment to the Company’s 2021 Equity Incentive Plan to amend the provision providing for an automatic share pool increase to include prefunded warrants in the calculation of… Filing
- Jun 5, 2026AnnouncementClimb Bio, Inc. announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody: • A translational pharmacokinetic/pharmacodynamic model derived from pooled non-human primate data projected healthy human exposure and dose-dependent IgA… Filing
- May 7, 2026ResultsReleased financial results. Filing
- May 5, 2026AnnouncementShared information with investors. Filing
- Apr 28, 2026AgreementClimb Bio, Inc., a Delaware corporation, entered into a securities purchase agreement with certain institutional accredited investors, including an affiliate of RA Capital Management, pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of… Filing
- Apr 3, 2026LeadershipClimb Bio, Inc. and Cindy Driscoll, its Senior Vice President, Finance and principal accounting officer, mutually agreed that Ms. Driscoll would separate from the Company, effective April 30, 2026. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementThe Company issued a press release announcing its pipeline progress and anticipated milestones for 2026, including the following pipeline updates: • In November 2025, the Company dosed the first patient in its PrisMN Phase 2 clinical trial of budoprutug in primary membranous nephropathy. • In… Filing
- Dec 31, 2025AnnouncementClimb Bio, Inc. filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, Inc., relating to a dispute concerning an Asset Purchase Agreement, dated as of January 11, 2024, between Acelyrin and Tenet Medicines, Inc., a wholly owned subsidiary of the… Filing
- Dec 11, 2025AgreementClimb Bio, Inc. entered into an exchange agreement with RA Capital Management, L.P. and an entity affiliated with RA Capital, pursuant to which the Exchanging Stockholder agreed to exchange an aggregate of 20,440,000 shares of the Company’s common stock, par value $0.0001 per share, beneficially… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Climb Bio financials
Famous investors that hold CLYM
4 of the 50 well-known investors we track reported holding CLYM in their latest 13F filing. The largest position is Ken Griffin's, worth $5.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 452,732 | $5.2M | 0.0% | -65% |
| Israel Englander · Millennium Management | Q3 2026 | 104,976 | $1.2M | 0.0% | -88% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 70,200 | $805K | 0.0% | -64% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 43,996 | $505K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named CLYM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 9, 2026 | RA Capital Management, L.P. | 13D/A | 33.0% |
| Nov 9, 2026 | RA Capital Management, L.P. | 13D/A | 33.0% |
| Nov 5, 2026 | FMR LLC | 13G/A | 15.0% |
| Nov 5, 2026 | FMR LLC | 13G/A | 15.0% |
| Oct 28, 2026 | Deerfield Mgmt, L.P. | 13G | 5.2% |
| Oct 28, 2026 | Deerfield Mgmt, L.P. | 13G | 5.2% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.0% |
Questions about Climb Bio, Inc. (CLYM) stock
Who owns the most CLYM stock?
The largest reported owner of Climb Bio, Inc. (CLYM) is Ra Capital Management, L.P., with 19.7% of the company. In total, 109 funds and institutions reported holding CLYM at the end of Q2 2026, together about 99% of the shares. See the largest owners.
Are CLYM insiders buying or selling?
In the last 12 months, CLYM insiders reported 3 open-market purchases worth $780K and 6 sales worth $2.7M. The latest trade was on Sep 15, 2026. See every trade.
What is the short interest in CLYM?
As of Oct 30, 2026, 10.61M CLYM shares were sold short, 18.1% of the shares outstanding, up 8.5% from the report before. At the average daily volume of 1.37M shares, buying them all back would take about 7.8 trading days (days to cover). See the history.
Which famous investors hold CLYM?
4 of the 50 well-known investors we track reported CLYM in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $5.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.